Stock AnalizQiagen NV QGEN
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2026 · data as of November 13, 2026
Qiagen NV (QGEN) is a healthcare company listed in the US with a market value of about $10.3B. In the twelve months to September 30, 2026 it had revenue of $2.1B and net income of $385M, a net margin of 18.2%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a P/E of 27.0, a price to free cash flow of 23.8, 5-year revenue growth of 2% a year, a 5-year average ROIC of 7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 37% below the current price.
Score: 2.0 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1B | $2.1B | $2.0B | $2.0B | $2.1B | $2.3B | $1.9B | $1.5B | $1.5B | $1.4B | $1.3B |
| Net income | $385M | $425M | $84M | $341M | $423M | $513M | $359M | -$41M | $190M | $40M | $80M |
| Free cash flow | $432M | $453M | $506M | $310M | $586M | $449M | $325M | $213M | $250M | $197M | $267M |
| EPS (diluted) | $1.85 | $2.06 | $0.41 | $1.66 | $2.05 | $2.49 | $1.74 | $-0.20 | $0.92 | $0.20 | $0.39 |
| Net margin | 18.2% | 20.3% | 4.2% | 17.4% | 19.8% | 22.8% | 19.2% | -2.7% | 12.7% | 2.9% | 6.0% |
| ROIC | — | 7.2% | 1.3% | 6.0% | 8.1% | 10.1% | 6.5% | -0.3% | 4.7% | 2.8% | 2.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $49.59, 1% below the current price; targets range from $40.00 to $53.00; the consensus rating is “Hold”; expected EPS is $2.49 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Qiagen NV’s P/E ratio?
About 27.0, based on the last twelve months of diluted earnings per share (forward P/E about 19.4).
Is Qiagen NV stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 37% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Qiagen NV pay a dividend?
Yes. The dividend yield is about 0.70%, and it has paid dividends for 1 years in our data.
Is Qiagen NV a good stock to buy?
We do not give buy or sell advice. Qiagen NV scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.